ATR 激酶是应对 DNA 复制应激（RS）的关键调节因子，在癌细胞中，许多遗传突变会导致 RS 水平升高，而 ATR 在维持复制叉的稳定性和促进细胞存活方面发挥着重要作用。抑制 ATR 可使癌细胞因复制叉崩溃和有丝分裂灾难而死亡，因此 ATR 成为癌症治疗的潜在靶点。目前，基于 ATR 抑制剂（ATRi）的临床试验正在开展，但尚未建立有效的治疗方案。

Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...

由苏州大学第一附属医院妇产科的Fang Wang，Yi Zhang，Jinhua Zhou 团队发表的名为“A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP ...

This strategic milestone marks Rakovina Therapeutics’ entry into one of the largest equity markets in Europe, providing increased visibility and accessibility to European and global investors. The ...

Announcing a new article publication for Zoonoses journal. Methicillin resistant Staphylococcus aureus (MRSA) and Vancomycin ...

In particular, there is a critical need for more effective small-molecule inhibitors of transcription factors, a major class of molecules that interact with other proteins and with DNA.

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

Shanghaitech University has identified thiazolidinedione compounds acting as DNA methyltransferase 3A (DNMT3A) inhibitors reported to be useful for the treatment of acute myeloid leukemia and ...

Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that it will present preclinical data on its ...